Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on Caco-2 and HepG2 cell lines

Journal of Pharmaceutical Sciences

Volumn 97, Issue 7, 2008, Pages 2844-2853

  Su, Jie ^a,b   Zhang, Ningning ^c   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Cancer chemotherapy; Emulsion; Lipids lipoproteins; Pharmacokinetics; Targeted drug delivery

Indexed keywords

APOLIPOPROTEIN; ETHINYLESTRADIOL; LOW DENSITY LIPOPROTEIN RECEPTOR; RETINOIC ACID; TRIBUTYRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG FORMULATION; DRUG SCREENING; EMULSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; NONHUMAN; RAT; TUMOR GROWTH; UPREGULATION;

EID: 52449119833     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21193     Document Type: Article

References (48)

1. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, DeLuca LM. 2000. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21:1271-1279.
2. Park EY, Dillard A, Williams EA, Wilder ET, Pepper MR, Lane MA. 2005. Retinol inhibits the growth of all-trans-retinoic acid-sensitive and all-trans-retinoic acid-resistant colon cancer cells through a retinoic acid receptor-independent mechanism. Cancer Res 65:9923-9933.
3. Witt O, Schmejkal S, Pekrun A. 2000. Tributyrin plus all-trans-retinoic acid efficiently induces fetal hemoglobin expression in human erythroleukemia cells. Am J Hematol 64:319-321.
4. Taimi M, Chen ZX, Breitman TR. 1998. Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide. Oncol Res 10:75-84.
5. Chen ZX, Breitman TR. 1994. Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 54:3494-3499.
6. Conley BA, Egorin MJ, Sridhara R, Finley R, Hemady R, Wu S, Tait NS, Van Echo DA. 1997. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmaco-dynamics. Cancer Chemother Pharmacol 39:291-299.
7. Muindi J, Frankel SR, Jr., Miller WH, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Jr., Warrell RP. 1992. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299-303.
8. Adamson PC, Pitot HC, Balis FM, Rubin J, Murphy RF, Poplack DG. 1993. Variability in the oral bio-availability of all-trans-retinoic acid. J Natl Cancer Inst 85:993-996.
9. Kawakami S, Suzuki S, Yamashita F, Hashida M. 2006. Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. J Control Release 110:514-521.
10. Kawakami S, Opanasopit P, Yokoyama M, Chansri N, Yamamoto T, Okano T, Yamashita F, Hashida M. 2005. Biodistribution characteristics of all-trans retinoic acid incorporated in liposomes and polymeric micelles following intravenous administration. J Pharm Sci 94:2606-2615.
11. Lin HS, Chean CS, Ng YY, Chan SY, Ho PC. 2000. 2-Hydroxy-propyl-beta- cyclodextrin increases aqueous solubility and photostability of all-trans-retinoic acid. J Clin Pharm Ther 25:265-269.
12. Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K. 1993. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 53:2100-2104.
13. Lim SJ, Kim CK. 2002. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 243:135-146.
14. Su J, He L, Zhang NN, Ho PC. 2006. Evaluation of tributyrin lipid emulsion with affinity to low-density lipoprotein: Pharmacokinetics in adult male Wistar rats and cellular activity on Caco-2 and HepG2 cell lines. J Pharmacol Exp Ther 316:62-70.
15. Su J, Ho PC. 2004. Preparation of tributyrin emulsion and characterization of the binding of the emulsion particles to low-density lipoprotein in vitro. J Pharm Sci 93:1755-1765.
16. Chanson NF, Lontie JFO, Gulik A, Férézou J, Carpentier YA. 2002. LDL binding to lipid emulsion particles: Effects of incubation duration, temperature, and addition of plasma subfractions. Lipids 37:573-580.
17. Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibanez OCM, Maranhao RC. 2005. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: In vitro and in vivo studies. Cancer Chemother Pharmacol 55:565-576.
18. Maranhao RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC, Rodrigues DG, Couto RD, Schreier S, Buzaid AC. 2002. Association of carmustine with a lipid emulsion: In vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol 49:487-498.
19. Maranhao RC, Roland IA, Toffoletto O, Ramires JA, Gonçalves RP, Mesquita CH, Pileggi P. 1997. Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to LDL receptors. Lipids 32:627-633.
20. Maranhao RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SMS, Coelho IJC, Meneghetti JC, Pileggi FJC, Chamone DAF. 1994. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 54:4660-4666.
21. Ho YK, Smith GL, Brown MS, Goldstein JL. 1978. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52: 1099-1114.
22. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. 2000. Human glioblastoma cell lines: Levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 60:2300-2303.
23. Leppälä J, Kallio M, Nikula T, Nikkinen P, Liewen-dahl K, Jääskeläinen J, Savolainen S, Gylling H, Hiltunen J, Callaway J, Kahl S, Färkkilä M. 1995. Accumulation of 99mTc-low-density lipoprotein in human malignant glioma. Br J Cancer 71:383-387.
24. Firestone RA. 1994. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconj Chem 5:105-113.
25. Guiso G, Rambaldi A, Dimitrova B, Biondi A, Caccia S. 1994. Determination of orally administered all-trans-retinoic acid in human plasma by high performance liquid chromatography. J Chromatogr B 656:239-244.
26. El Mansouri S, Tod M, Leclerq M, Petitjean O, Perret G, Porthault M. 1995. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). Drug Metab Dispos 23:227-231.
27. Shelley RS, Jun HW, Price JC, Cadwallader DE. 1982. Blood level studies of all-trans- and 13-cisretinoic acids in rats using different formulations. J Pharm Sci 71:904-907.
28. Wasan KM, Cassidy SM, Kennedy AL, Peteherych KD. 2000. Lipoprotein isolation and analysis from serum by preparative ultracentrifugation. In: Drew AF, editor. Atherosclerosis: Experimental methods and protocols. Totowa: Humana Press. pp 27-35.
29. Osborne JC. 1986. Delipidation of plasma lipoproteins. Methods Enzymol 128:213-222.
30. Sata T, Havel R, Jones A. 1972. Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans. J Lipid Res 13:757-768.
31. Greenspan P, Gutman RL. 1993. Detection by Nile Red of agarose gel electrophoresed native and modified low-density lipoprotein. Electrophoresis 14: 65-68.
32. Eklund A, Sjöblom L. 1986. Improved banding pattern of rat plasma lipoproteins developed by agarose gel electrophoresis at pH 7.0. Biochim Biophys Acta 877:135-140.
33. Chao Y, Windier EE, Chen GC, Havel RJ. 1979. Hepatic catabolism of rat and human lipoproteins in rats treated with 17α-ethynyl estradiol. J Biol Chem 254:11360-11366.
34. Adamson PC, Balis FM, Smith MA, Murphy RF, Godwin KA, Poplack DG. 1992. Dose-dependent pharmacokinetics of all-trans-retinoic acid. J Natl Cancer Inst 84:1332-1335.
35. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. 2006. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66:9299-9307.
36. Hwang SR, Lim SJ, Park JS, Kim CK. 2004. Phos-pholipid-based microemulsion formulation of all-trans-retinoic acid for parenteral administration. Int J Pharm 276:175-183.
37. Shawer M, Greenspan P, Øie S, Lu DR. 2002. VLDL-resembling phospholipid-submicron emulsion for cholesterol-based drug targeting. J Pharm Sci 91:1405-1413.
38. Maranhao RC, Cesar TB, Pedroso-Mariani S, Hirata MH, Mesquita CH. 1993. Metabolic behavior in rats of a non-protein microemulsion resembling LDL. Lipids 28:691-696.
39. Saito H, Tanaka M, Okamura E, Kimura T, Nakahara M, Handa T. 2001. Interactions of phosphatidylcholine surface monolayers with triglyceride cores and enhanced ApoA-1 binding in lipid emulsions. Langmuir 17:2528-2532.
40. Rensen PCN, Herijgers N, Netscher MH, Meskers SCJ, Van Eck M, Van Berkel TJC. 1997. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res 38:1070-1084.
41. Saito H, Minamida T, Arimoto I, Handa T, Miyajima K. 1996. Physical states of surface and core lipids in lipid emulsions and apolipoprotein binding to the emulsion surface. J Biol Chem 271:15515-15520.
42. Adamson PC. 1994. Pharmacokinetics of all-trans retinoic acid: Clinical implications in acute promyelocytic leukemia. Semin Hematol 31:14-17.
43. Mehta K, Sadeghi T, McQueen T, Lopez-Berestein G. 1994. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res 18:587-596.
44. Chung NS, Wasan KM. 2004. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 56:1315-1334.
45. Ehrlich M, Boll W, Van Oijen A, Hariharan R, Chandran K, Nibert ML, Kirchhausen T. 2004. Endocytosis by random initiation and stabilization of clathrin-coated pits. Cell 118:591-605.
46. Motley A, Bright NA, Seaman MNJ, Robinson MS. 2003. Clathrin-mediated endocytosis in AP-2-depleted cells. J Cell Biol 162:909-918.
47. Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS, Goldstein JL, Deisenhofer J. 2002. Structure of the LDL receptor extracellular domain at endosomal pH. Science 298:2353-2358.
48. Davis CG, Goldstein JL, Sudhof TC, Anderson RG, Russell DW, Brown MS. 1987. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 326:760-765.